Latest Otc Pharmaceuticals News

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.